Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Fig. 5

In vivo reconstitution of healthy human hematopoietic compartments in tissues. Comparable profile between TEG001 and TEG-LM1 mock group of reconstituted healthy human hematopoietic cellular subsets in spleen and bone marrow, including total human CD45+ leukocytes (a), CD14+ monocytes (b), B cells (c), T cells (d) and CD34+ progenitor cells (e) as measured by flow cytometry. Shown in the data from individual mouse (represented by different symbols) of both TEG001 (filled symbol) and TEG-LM1 mock (open symbol) group (n = 3 mice/group)

Back to article page